Epitalon vs SS-31 (elamipretide) — Research Comparison (2026)

Laboratory reference. Epitalon and SS-31 (elamipretide) are research compounds compared here on mechanism, pharmacokinetics, dosing math, and reported outcomes. Not medical advice.

1. At-a-Glance Comparison

| Property | Epitalon | SS-31 (elamipretide) | |---|---|---| | Class | Pineal tetrapeptide | Mitochondria-targeted tetrapeptide | | Primary mechanism | putative telomerase induction, pineal/circadian modulation, melatonin-axis interaction | selective cardiolipin binding on the inner mitochondrial membrane → preserved cristae architecture and improved electron-transport efficiency | | Half-life | ~30-90 min SC (estimated) | ~2-4 h SC | | Typical research dose | 5-10 mg/day for 10-20-day cycles SC | 1-40 mg/day SC depending on protocol |

2. Mechanism of Action

Epitalon acts through putative telomerase induction, pineal/circadian modulation, melatonin-axis interaction. [SS-31](/research/hubs/ss-31) (elamipretide) acts through selective cardiolipin binding on the inner mitochondrial membrane → preserved cristae architecture and improved electron-transport efficiency. Although both compounds are studied for related endpoints, their receptor biology is distinct — this is the most important determinant of which compound is better suited to a given research question.

3. Pharmacokinetics

Epitalon has a plasma half-life of approximately ~30-90 min SC (estimated), while SS-31 (elamipretide) sits at ~2-4 h SC. Half-life governs both dosing frequency and the shape of the resulting tissue exposure curve. A short half-life produces sharper, pulsatile exposure that more closely mimics endogenous signaling; a longer half-life produces sustained exposure that simplifies dosing schedules but blunts pulsatility.

4. Dosing Differences

Standard research doses are 5-10 mg/day for 10-20-day cycles SC for Epitalon and 1-40 mg/day SC depending on protocol for SS-31 (elamipretide). These ranges should be treated as starting points anchored in published literature — every protocol should still establish its own dose-finding rationale based on the receptor biology above.

5. Strengths

Epitalon: Long-running Russian research base; simple cycle design; subjective sleep/circadian effects reported.

SS-31 (elamipretide): Cleanly defined mitochondrial mechanism; published trials in heart failure, primary mitochondrial myopathy, and ophthalmology endpoints.

6. Limitations

Epitalon: Mechanism still debated; large-cohort RCT data limited; cycle-based protocol design.

SS-31 (elamipretide): Higher cost; mitochondrial-disease evidence is the strongest, with longevity-endpoint extrapolation still pending.

7. Choosing Between Them for a Research Question

Research questions targeting circadian/sleep/longevity-via-telomerase endpoints favor epitalon. Research questions targeting mitochondrial bioenergetics, cardiolipin biology, or organ-level mitochondrial dysfunction favor SS-31.

8. Stacking and Concomitant Use

Researchers occasionally evaluate both compounds inside a single protocol when their mechanisms are non-overlapping and the endpoint of interest sits at the intersection. When stacking, isolate the contribution of each compound by sequencing the dose-finding work — establish a baseline with one compound, then add the second — rather than introducing both simultaneously.

9. Quality and Sourcing Considerations

For either compound, the COA / HPLC / mass-spec triad is the minimum quality envelope. Differences in lot purity are a frequent confounder that gets attributed to "compound choice" when it is actually a sourcing issue. See the linked Lab Methods guides for verification protocols.

10. Safety Considerations

The safety profile of each compound follows its mechanism. Epitalon requires monitoring focused on pineal tetrapeptide effects, while SS-31 (elamipretide) requires monitoring focused on mitochondria-targeted tetrapeptide effects. Adopt the relevant Safety Profile guide as the monitoring baseline for whichever compound is selected.

11. Verdict

Different layers of longevity research. Epitalon sits at the circadian/telomere layer; SS-31 sits at the mitochondrial-membrane layer.

---

*For deeper detail, see the Mechanism, Dosing, Reconstitution, and Safety guides for each compound.*